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A Comprehensive Analysis of Ontogeny of 
Renal Drug Transporters: mRNA Analyses, 
Quantitative Proteomics, and Localization
Kit Wun Kathy Cheung1,2,3,†, Bianca D. van Groen4,†, Edwin Spaans4,5, Marjolein D. van Borselen6,  
Adrianus C.J.M. de Bruijn7, Ytje Simons-Oosterhuis7, Dick Tibboel4, Janneke N. Samsom7, Robert M. Verdijk8, 
Bart Smeets9, Lei Zhang10, Shiew-Mei Huang2, Kathleen M. Giacomini1,† and Saskia N. de Wildt4,6,*,†
Human renal membrane transporters play key roles in the disposition of renally cleared drugs and endogenous 
substrates, but their ontogeny is largely unknown. Using 184 human postmortem frozen renal cortical tissues 
(preterm newborns to adults) and a subset of 62 tissue samples, we measured the mRNA levels of 11 renal 
transporters and the transcription factor pregnane X receptor (PXR) with quantitative real- time polymerase chain 
reaction, and protein abundance of nine transporters using liquid chromatography tandem mass spectrometry 
selective reaction monitoring, respectively. Expression levels of p-glycoprotein, urate transporter 1, organic anion 
transporter 1, organic anion transporter 3, and organic cation transporter 2 increased with age. Protein levels of 
multidrug and toxin extrusion transporter 2-K and breast cancer resistance protein showed no difference from 
newborns to adults, despite age- related changes in mRNA expression. Multidrug and toxin extrusion transporter 1, 
glucose transporter 2, multidrug resistance-associated protein 2, multidrug resistance-associated protein 4 (MRP4), 
and PXR expression levels were stable. Using immunohistochemistry, we found that MRP4 localization in pediatric 
samples was similar to that in adult samples. Collectively, our study revealed that renal drug transporters exhibited 
different rates and patterns of maturation, suggesting that renal handling of substrates may change with age.
Renal membrane transporters, which are located on the apical and 
basolateral sides of the tubular epithelium, are key players in tu-
bular secretion and reabsorption of a plethora of endogenous and 
exogenous compounds in the kidneys.1,2 Because of their role in 
renal elimination, many transporters in the kidneys play critical 
roles in the disposition, efficacy, and toxicity of drugs. Notably, 
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Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE 
TOPIC?
 Membrane transporters in the human kidney play major 
roles in the disposition of many drugs and endogenous sub-
stances. Pediatric patients often exhibit age- related differences 
in drug disposition. This may be related to ontogenic changes in 
the expression levels of renal transporters, but knowledge is 
lacking.
WHAT QUESTION DID THIS STUDY ADDRESS?
 How do gene expression and protein abundance of 11 renal 
membrane transporters change with age?
WHAT DOES THIS STUDY ADD TO OUR 
KNOW LEDGE?
 By analyzing 184 human postmortem kidney samples 
from newborns to adults, our study showed that 11 renal 
drug transporters exhibited different patterns of maturation, 
with most changes occurring in children <2 years of age.
HOW MIGHT THIS CHANGE CLINICAL PHARMA­
COLOGY OR TRANSLATIONAL SCIENCE?
 These data, which suggest a mechanism for age- related 
changes in drug disposition, may be used in modeling and 
simulation to predict drug dosing in children. Our findings set 
the stage for future research in the mechanisms underlying on-
togenic changes in the expression of renal drug transporters.
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renal drug transporters have received increasing regulatory at-
tention in recent years, highlighting their significance in drug 
disposition.3–6
Interindividual variation in expression levels and functional 
activities of membrane transporters can affect the homeostasis of 
endogenous substrates, as well as the pharmacokinetics and phar-
macodynamics of drugs.1 As a result of developmental changes 
in key transporters and enzymes, levels of endogenous substrates, 
such as metabolites, nutrients, antioxidants, and hormones, 
change as children grow.7 Reduced hepatic clearance of the opi-
oid morphine in newborns and young infants was reported.8 This 
was suggested due to significantly lower hepatic levels of both 
the drug-metabolizing enzyme uridine 5- diphosphoglucuronic 
acid glucuronyl transferase 2B7 and the organic cation trans-
porter (OCT) 1 in young pediatric populations compared with 
adults.9,10 In contrast to the liver, less is known about the matura-
tion and ontogeny pattern of renal membrane transporters. This 
knowledge gap limits the ability to predict the pharmacokinetics 
of renally eliminated drugs in children, which may be critical for 
rational dosing and drug efficacy and safety. Thus, there is an ur-
gent need to understand the ontogeny of human drug transporters 
in the kidneys.
The current study aimed to identify age- related differences in 
gene expression and protein abundance of renal transporters. We 
chose to focus on renal transporters with demonstrated clinical 
relevance in drug disposition, and those that handle various en-
dogenous and exogenous substances important for developing 
children11,12 (i.e., breast cancer resistance protein (gene name/pro-
tein name ABCG2/BCRP), multidrug and toxin extrusion pro-
tein (SLC47A/MATE) 1 and 2- K, multidrug resistance protein 
1 (ABCB1/MDR1/p-glycoprotein (P-gp)), multidrug resistance- 
associated protein (ABCC/MRP) 2 and 4, and urate transporter 1 
(SLC22A12/URAT1) on the apical site of the membrane and glu-
cose transporter 2 (SLC2A2/GLUT2), organic anion transporter 
1 (SLC22A6/OAT1) and 3 (SLC22A8/OAT3), and SLC22A2/
OCT2 located on the basolateral site. In an effort to explore a reg-
ulatory mechanism for maturation of transporter expression, we 
also studied renal gene expression of the nuclear pregnane X recep-
tor (PXR) in relation to the transporter expression levels.13
In addition, altered localization of a transporter may introduce 
variation in pharmacokinetics of transporter substrates. However, 
little is known about the localization of transporters during devel-
opment of the kidneys. MRP4 is an apical efflux transporter in-
volved in transport of a range of endogenous molecules, including 
cyclic nucleotides, urate and conjugated steroid hormones, and 
drugs that are used in children, including antivirals and diuretics.14 
We performed immunohistochemistry as a proof- of- concept to vi-
sualize the location of MRP4 in our pediatric kidney tissues.
RESULTS
Two sample sets, which provided a total of 184 postmortem 
renal cortical tissues, were analyzed in this study (Figure 1 and 
Table 1). Sample set 1 represented 62 samples from individuals 
of different ages ranging from preterm newborns (gestational age 
(GA) > 24 weeks, postnatal age (PNA) 1 day) to adult donors (old-
est 75 years). The 122 tissues in sample set 2 were from African 
American and white term newborns to adults. No statistical differ-
ence was observed in gene expression or protein abundance levels for 
any of the transporters between boys and girls and between African 
Americans and whites (Tables S1–S3); hence, subsequent analyses 
were performed by combining both sexes and all ethnic groups.
Relative mRNA quantitation
All 184 tissues were processed for mRNA quantitation (Figure 2 
and Table S4). The mRNA levels of the selected transporters were 
detected successfully in all samples, with the exception of MATE1 
in two samples. Glyceraldehyde 3- phosphate dehydrogenase 
mRNA expression did not change with age (rs = −0.12; P = 0.119).
Overall, a large variability in the developmental changes in 
transporter mRNA levels was observed (Figure 2 and Table 
S4). MATE2- K, P- gp, URAT1, OAT1, OAT3, and OCT2 
levels in premature and/or term newborns were significantly 
lower than in the older age groups. In contrast, term newborns 
showed significantly higher BCRP mRNA levels than children 
Figure 1 Sample analysis scheme. The subset of 62 samples from sample set 2 for quantitative proteomics consisted of the 57 African 
American samples and 5 adult white samples (see Table 1). BCRP, breast cancer resistance protein; GLUT, glucose transporter; MATE, 
multidrug and toxin extrusion protein; MDR, multidrug resistance protein; MRP, multidrug resistance-associated protein; OAT, organic anion 
transporter; OCT, organic cation transporter; PXR, pregnane X receptor; URAT, urate transporter.
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and adolescents. MATE1, MRP2, MRP4, GLUT2, and PXR 
levels were not different between all age groups (preterm new-
born, term newborn, infants, children, adolescents, and adults).
Proteomics
Sixty- two samples were assessed for transporter protein levels 
(Figure 3 and Table S5). The median total membrane protein 
Table 1 Overview of sample size and age range of sample sets 1 and 2
Age group
Number of samples Age range
Sample set 1 Sample set 2
Total Gestational age Postnatal ageRace unknown White African American
Preterm newborns 9 − − 9 34.00 (24.00–36.71) weeks 1.29 (0.14–4.00) weeks
Term newborns 8 10 1 19 NA 1.29 (0.14–3.86) weeks
Infants 21 30 30 81 NA 17.86 (4.14–103.00) weeks
Children 7 15 16 38 NA 4.74 (2.00–11.56) years
Adolescents − 5 5 10 NA 13.38 (12.48–15.26) years
Adults 17 5 5 27 NA 45.00 (16.75–75.00) years
Total 62 65 57 184
122
NA, not available.
Figure 2 Relative mRNA expression of 11 renal membrane transporters and pregnane X receptor in different age groups. Transporters 
are grouped according to their primary localization in the kidney (basolateral or apical). The bar represents the median for each age group. 
*P < 0.05, **P < 0.01, ***P < 0.001. BCRP, breast cancer resistance protein; GAPDH, glyceraldehyde 3- phosphate dehydrogenase; GLUT, 
glucose transporter; MATE, multidrug and toxin extrusion protein; MDR, multidrug resistance protein; MRP, multidrug resistance-associated 
protein; OAT, organic anion transporter; OCT, organic cation transporter; PXR, pregnane X receptor; URAT, urate transporter.
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yield for all samples was 49.5 mg/g (range 41.7–62.1 mg/g) renal 
cortical tissue. All nine transporters were detected and quanti-
fied in our samples. P- gp was found to be the most abundant 
transporter, whereas MATE2- K was the least abundant (Table 
S5).
P- gp, URAT1, OAT1, OAT3, and OCT2 protein abundance 
levels were significantly lower in term newborn and infants than 
in the older age groups (Figure 3). Sigmoidal maximum effect 
(Emax) models were used to fit the protein abundance levels of 
these five transporters, and all but URAT1 expression data con-
formed to the model (Figure 4a). OCT2 and P- gp expressions 
increased at a faster rate than OAT1 and OAT3, as evidenced by 
the younger age at which half of the adult expression was reached 
(TM50). Moreover, the transporters OCT2 and P- gp shared a 
similar maturation pattern, as well as the transporters OAT1 and 
OAT3 (Figure 4b). No difference in protein abundance levels 
was found among age groups for BCRP, MATE1, MATE2- K, 
and GLUT2.
Correlation between mRNA expression and protein 
abundance levels
Potential correlation between mRNA expression and protein 
abundance levels of the transporters was investigated (Figure S1). 
Significant correlation was found for MATE1, P- gp, URAT1, 
OAT3, and OCT2.
Intertransporter correlation
To assess the potential shared expression regulation, we studied 
the correlation of mRNA expression and protein abundance levels 
between transporters (Table 2). Levels of OAT1 and OAT3 were 
the most significantly correlated.
Correlation between PXR and transporter mRNA expression
Weak negative correlations with PXR were found for MATE1 
(rs = −0.27; P = 0.035), MRP2 (rs = −0.29; P = 0.021), and 
OCT2 (rs = −0.26; P = 0.043), whereas no correlation was found 
for MATE2-K, P- gp, MRP4, OAT1, and OAT3.
Figure 3 Protein abundance levels of nine renal membrane transporters in different age groups. The bar represents the median for each age 
group. Term newborn and infants were combined here for analysis because there was only one term newborn included for this part of the study. 
*P < 0.05, **P < 0.01, ***P < 0.001. GLUT, glucose transporter; MATE, multidrug and toxin extrusion protein; MDR, multidrug resistance 
protein; MRP, multidrug resistance-associated protein; OAT, organic anion transporter; OCT, organic cation transporter; PXR, pregnane X receptor; 
URAT, urate transporter.
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Localization of MRP4 in pediatric kidney tissue
As a proof- of- concept, postmortem kidney tissues of 43 pediatric 
patients (GA > 24 weeks, PNA 2 days to 14 years old) and 1 adult 
were analyzed. Positive MRP4 immunostaining was detected 
as early as 27 weeks of gestation (PNA 9 days), despite negative 
staining found in three tissues from one child and two adoles-
cents. For all the positive stained samples, MRP4 was found to 
be located at the apical side of the proximal tubule (Figure 5a,b). 
Figure 4 Ontogeny of protein abundance of P-gp, OAT1, OAT3, and OCT2 as described by sigmoidal maximum effect (Emax) model. Individual 
sigmoidal curves are presented in (a) (solid lines). Dashed lines represent the 95% confidence bands. Superimposing the sigmoidal curves 
as presented in (b) showed that the pair transporters, P-gp/OCT2 and OAT1/OAT3, shared similar maturation patterns. OAT, organic anion 
transporter; OCT, organic cation transporter; P-gp, p-glycoprotein; PNA, postnatal age; TM50, half of the adult expression was reached.
Table 2 Intertransporter Spearman correlations
Apical Basolateral
BCRP MATE1 MATE2- K MDR1 MRP2 MRP4 URAT1 GLUT2 OAT1 OAT3 OCT2
Apical
BCRP − 0.69 0.44 NA NA 0.59 0.43
MATE1 − 0.63 0.36
0.57
0.74 0.50
0.57
0.44 0.53
0.61
0.54
0.54
0.62
0.57
MATE2- K − 0.39 0.57 0.51 0.47 0.59 0.56 0.49
MDR1 − 0.47 0.32
0.56
0.37 0.52
0.72
0.49
0.60
0.57
0.67
MRP2 − NA NA 0.79 0.83 0.67
MRP4 − NA NA
URAT1 − 0.42 0.54
0.49
0.50
0.49
0.46
0.52
Basolateral
GLUT2 − 0.64 0.64 0.49
OAT1 − 0.85
0.83
0.74
0.70
OAT3 − 0.73
0.72
OCT2 −
All figures in italics are the mRNA expressions.
All figures in boldface are protein expressions. All reached P < 0.0001. Data not presented if P > 0.001.
GLUT, glucose transporter; MATE, multidrug and toxin extrusion protein; MDR, multidrug resistance protein; MRP, multidrug resistance-associated protein; NA, 
not available; OAT, organic anion transporter; OCT, organic cation transporter; PXR, pregnane X receptor; URAT, urate transporter.
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See Figure 5c for the negative control. Although the examples 
showed lower staining at 3.3 weeks (Figure 5a) than 3.1 years old 
(Figure 5b), no statistically significant age- related changes were 
detected in the semiquantification of the staining in the whole 
sample set (Figure 5d).
DISCUSSION
This study, to our best knowledge, is the first to comprehensively 
describe the ontogeny of human renal membrane transporters 
via mRNA expression analysis and quantitative proteomics in 
tissues representing a large span of ages. Albeit data on devel-
opmental changes in transporter mRNA expression in animals 
were reported previously,15–19 cross- species differences limit ex-
trapolation, especially concerning the rates of maturation.20
Our study revealed two major findings with respect to the de-
velopmental maturation of renal transporters: (i) the expression of 
most of the transporters characterized in this study increased with 
age during the earliest developmental periods (<2 years old), and 
(ii) maturation pattern was transporter- dependent. Additionally, 
we observed that: (i) there were maturational differences between 
mRNA expression and protein abundance, (ii) there were cor-
relations between the expression levels of various transporters, 
(iii) PXR seems to play a minimal role in regulating mRNA expression 
of transporters in the kidney, and (iv) stable MRP4 mRNA expression 
was accompanied by proper apical localization during development.
Transporter- dependent maturation patterns during the 
earliest developmental periods
The findings that most of the studied transporters showed a 
transporter- dependent age- related increase in their expression 
levels, especially during the earliest years of life, were expected. 
Renal membrane transporters play critical roles in elimination 
and detoxification pathways in the body. They work in concert 
with enzymes in the kidneys, as well as enzymes and transporters 
in other organs, such as the intestine and liver, to mediate the re-
moval of ingested potential harmful compounds, such as toxins 
derived from food, environmental toxins, drugs, and their me-
tabolites.7 During infancy, dietary exposure to potential toxins 
is limited and begins to increase as infants are switched from an 
exclusively milk diet to foods that may contain more toxins.21,22 
Thus, detoxification pathways are increasingly needed as the diet 
of infants expands and diversifies into childhood.
Furthermore, besides changes in dietary intake and nutritional 
requirement, ontogeny of renal transporters can alter the dispo-
sition of endogenous compounds, suggesting important develop-
mental roles for these renal transporters. Both BCRP and URAT1 
are thought to play a clear role in uric acid (UA) homeostasis.23,24 
It was previously reported that the fractional excretion of UA 
(FEUA; the % of filtered UA not reabsorbed by the tubules), was 
30–40% in term newborns < 5 days old, which then decreased 
to 8–10% in children of 3 years old.25–27 Our transporter matu-
ration data, in addition to age- related physiological changes (e.g., 
urinary acidification and concentration ability), may explain this 
observation: the decreasing BCRP mRNA expression from birth is 
accompanied by an increased expression of URAT1, a reabsorptive 
transporter, from birth until childhood, resulting in a net decrease 
in UA excretion.25,27 Interestingly, sex- related differences in FEUA 
especially during adolescence were reported, which could be due 
to differences in proximal tubular secretion of UA.27 Yet, no sig-
nificant sex- related differences were found in our study consisting 
Figure 5 Apical proximal tubule localization of multidrug resistance-associated protein (MRP4) (arrow) by immunohistochemically staining in 
postmortem tissue of samples with (a) gestational age (GA) of 27.7 weeks; postnatal age (PNA) age 3.3 weeks, and (b) GA of 40.0 weeks; PNA 
3.1 years (c) represents the negative control, and (d) the semiquantification of MRP4 staining in various age groups: negative (0), low staining 
(+1), or high staining (+2).
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mainly of pediatric samples. As the influence of sex seems to be 
transporter- specific in adults,28 follow- up studies with more sam-
ples and also with other transporters that handle UA, such as 
GLUT9, would be needed to fully understand the changes in 
FEUA.
In vivo pharmacokinetic data of drugs that are transporter sub-
strates may be used to support our expression data. However, renal 
elimination of these drugs is accomplished not only by active tubu-
lar secretion facilitated by various transporters but also by glomer-
ular filtration, which is also subjected to age- dependent changes. 
As children grow and develop, the glomerular filtration rate (GFR) 
matures and is predicted to reach 50% of adult values by 2 months 
PNA and 90% of adult values by 1 year of age.29 Although the full 
complement of nephrons in each kidney is complete around GA 
36 weeks,30 GFR continues to develop as a result of increases in 
kidney blood flow, improvements in filtration coefficients, and 
maturation of the tubules. Our findings that there are age- related 
changes in transporter expression early in life (<2 years) support 
the notion that active tubular secretion matures in parallel with 
GFR maturation. Thus, observed age- related changes in pharma-
cokinetics of transporter substrates are likely due to a combina-
tion of both maturation in transporter expression and GFR. For 
instance, after hepatic metabolism, the antiviral drug valacyclovir 
undergoes renal elimination via glomerular filtration and active 
tubular secretion likely by OAT1/3.31 Apparent clearance of vala-
cyclovir in infants < 3 months old is 50% lower than that in young 
children.31 The GFR in infants < 3 months old is expected to be 
>50%,29 and, therefore, this discrepancy may be explained by our 
findings that the TM50 of OAT1 and OAT3 was ~ 4 and 8 months 
(Figure 4a). Famotidine, an OAT3 substrate used in the treatment 
of gastritis, provides another example of maturational changes in 
both GFR and secretory transporters.32 Given the complex devel-
opmental changes in renal elimination processes, our data could be 
integrated into physiologically- based pharmacokinetic models to 
improve prediction of pediatric drug clearance. When doing so, 
scaling factors should be used to correct for membrane protein 
yield and total organ weight.
Other observations from data analysis
The abundance pattern of the transporters in our adult sam-
ples was assessed. P- gp has the highest abundance, followed by 
URAT1, GLUT2, OCT2, OAT3, MATE1, OAT1, BCRP, and 
MATE2- K. This abundance pattern is different from that re-
ported in Prasad et al.,33 where OCT2 was the most abundant 
transporter, followed by OAT1, MATE1, OAT3, and P- gp. This 
discrepancy could be due to actual intersample variation in expres-
sion levels of the transporters, or to differences in the inclusion 
criteria and quality of the tissue samples used in the studies. In 
addition, our study also showed much higher absolute abundance 
for most proteins in our adult samples compared with other stud-
ies.34 As Li et al.35 suggested, such interlaboratory difference may, 
in part, be explained by different instrumental performance and 
varying tissue handling techniques.
Differences in the patterns and rates of change among mRNA ex-
pression and protein abundance levels of various transporters were 
noticed. For example, age- related changes were found in BCRP, 
GLUT2, and MATE2- K mRNA levels but not in protein abun-
dance levels. This may suggest maturational differences in the reg-
ulation of gene transcription and post- translational processing. For 
gene transcription, alternative splicing is suggested to occur due to 
developmental signals.36 Some of the alternatively spliced mRNA 
transcripts may not be translated into the protein of interest but 
will be quantified by quantitative real- time polymerase chain reac-
tion as the total mRNA expression could be derived from a mixture 
of different transcripts of the targeted gene.37 Quantitative pro-
teomic overcomes this challenge by measuring the actual expres-
sion of the protein of interest. This process could explain the lack 
of correlation between mRNA and protein expression.
Our data showed that transporter expression is correlated among 
various transporters. The strong correlation between expression of 
OAT1 and OAT3 is not surprising as they are located in adjacent 
regions on chromosome 11.38 Moreover, they are both regulated 
by the transcription factors hepatocyte nuclear factor 1α and 1β, 
which increase their transcription.39 Our study of transcription 
factors was confined to PXR, and in agreement with previously 
reported findings; PXR mRNA levels in kidneys were low in all 
age groups compared with the mRNA levels of the studied trans-
porters.28,40,41 Thus, PXR seems to have a minor role in regulating 
transporter gene expression in the kidneys than in other organs. 
This is supported by findings in mice, where the potent rodent 
PXR activator pregnenolone- 16α- carbonitrile induced transporter 
expression in the liver and intestine, but not in the kidneys.40 More 
research is needed to identify the developmental triggers by which 
transcription of transporters increase and decrease. Moreover, the 
relationship between transcription factors maintaining basal ex-
pression level, like the hepatocyte nuclear factor family, and renal 
transporter expression should be studied.
Detoxification involves the interplay between enzymes and 
transporters that are ubiquitously expressed in tissues throughout 
the human body. P- gp expression levels in the liver only reached 
50% of adult expression levels at 2.9 years of age,9 whereas our re-
sults suggested that full adult levels were achieved in the kidneys 
by that age. For BCRP, our results for mRNA expression in the 
kidneys were consistent with that in the liver, which showed a de-
cline from newborns to adults.42 As more transporter ontogenetic 
data in different organs become available, more reliable prediction 
in transporter- mediated substrate disposition on the whole- body 
level during development will be achieved.
Potential limitations
Certain limitations are present in this study. In addition to age, 
there are other potential factors, such as the use of comedications 
and inflammation that can influence transporter expression and 
thereby contribute to the expression variability.43 The impact of 
acute and chronic inflammation on transporter expression and 
activity is related to the activity of multiple proinflammatory 
cytokines.44 The exact mechanism remains unknown and may 
be related to various nuclear receptors and transcription factors. 
Similarly, certain medications and environmental toxins could 
lead to activation of nuclear receptor pathway, and could, there-
fore, influence the transporter expression.44,45 The underlying 
reason for death of our tissue donors is heterogeneous and so are 
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the exposure of drugs and environmental toxins. Yet, despite all 
these inevitable differences, significant changes in the expression 
levels by age were still observed. However, due to the lack of de-
tailed clinical data available for our samples, these factors could 
not be explored. Although protein and mRNA levels in the post-
mortem samples used in our study were excellent, the amount of 
degradation in these levels from death to freezing is not known. 
Degradation may vary among samples, and may result in reduced 
absolute levels and increased variability in expression level mea-
surements. Moreover, with the exception of PXR, we did not 
study the ontogeny of other transcription factors and proteins in-
volved in gene and protein regulation; therefore, the mechanisms 
underlying the ontogeny of transporters observed in this study 
are not known. Finally, mRNA expression, protein abundance 
and transporter activity ex vivo and in vivo studies are needed to 
confirm the implications of our results to drug disposition in the 
kidneys.
CONCLUSIONS
These results showed that the ontogeny of certain renal membrane 
transporters displayed an age- dependent pattern, suggesting that 
the clearance of exogenous and endogenous substrates for these 
kidney transporters are subject to transporter- specific age- related 
changes. Although future work is clearly needed in refining pre-
dictive models for pediatric drug disposition, leveraging our ex-
pression data in modeling and simulation strategies may improve 
predictability of pediatric drug disposition and exposure models. 
Importantly, our findings set the stage for future research in un-
derstanding the mechanisms of developmental changes in renal 
drug transporters.
METHODS
Tissue procurement and sample characteristics
Two sample sets were analyzed, and the demographic information of do-
nors is reported in Table 1. Age groups were predefined based on the 
International Council for Harmonisation guidelines: preterm newborns 
(PNA 0–28 days; GA < 37 weeks), newborns (PNA 0–28 days), infants 
(1–24 months old), children (2–12 years old), adolescents (12–16 years 
old), and adults (>16 years old).4 Sample set 1 consisted of postmortem 
autopsy kidney samples and surgical adult kidney samples from the 
Erasmus MC Tissue Bank, Rotterdam, The Netherlands. Sample set 2 
consisted of 122 human postmortem frozen renal cortical tissues (donors 
aged 1 day to 30 years old), which were obtained from National Institutes 
of Health NeuroBioBank at the University of Maryland, Baltimore, 
MD. Tissues, which were selected for having no renal abnormalities in 
pathology and primary diagnosis, were procured at the time of autopsy 
within 48 hours after death and were stored at −196°C (sample set 1) and 
−80°C (sample set 2) for later use. The quantitative proteomic analysis 
was done completely in the United States on the subset of samples from 
sample set 2 and the immunohistochemistry was performed entirely in 
the Netherlands on sample set 1. Gene expression analysis was conducted 
in both laboratories, and the data from the two sources were first ana-
lyzed separately, followed by a combined analysis. Combined analysis was 
deemed appropriate as no significant differences were observed between 
the expression levels of six transporter genes (MATE1, MATE2, P- gp, 
OAT1, OAT3, and OCT2) in adult samples obtained in the United 
States and in the Netherlands. Furthermore, developmental patterns in 
expression of the transporters in the two sample sets showed comparable 
results.
mRNA expression
Figure 1 illustrates the sample analysis scheme. For sample set 1, the pro-
tocol on quantitative real- time polymerase chain reaction is described in 
Material S1 and Table S6. For sample set 2, the protocol described in 
Chen et al.46 was followed with slight modifications (Material S1).
Quantitative proteomics using liquid chromatography 
tandem mass spectrometry with selective reaction 
monitoring
Quantitative proteomics was only performed in sample set 2 (Figure 1). 
Unless otherwise stated, reagents from MyOmicsDx (Towson, MD) 
were used. Details of the liquid chromatography and mass spectrom-
etry method and parameters are described in the supplemental docu-
ments (Material S2). Briefly, membrane proteins were extracted from 
the renal cortical tissues using MyPro- MembraneEx buffer. The total 
extracted membrane protein concentration was determined using the 
Bicinchoninic acid assay protein assay kit. The membrane protein sam-
ples were then processed by MyOmicsDx using the filter- aided sample 
preparation method.47
Five peptides were chosen for each transporter as selective reaction 
monitoring (SRM) quantifying targets and six best transitions per pep-
tide precursors were selected for SRM quantification (Table S7). Peptide 
samples that were previously reconstituted in MyPro- Buffer 3 were spiked 
with MyPro- SRM Internal Control Mixture and were subjected to SRM 
analysis. The peptide samples were eluted through an online Agilent 1290 
HPLC system into the Jet Stream ESI source of an Agilent 6495 Triple 
Quadrupole Mass Spectrometer (Agilent, Santa Clara, CA).
Quantitative data were imported into Skyline 3.1.48 The abundance of a 
target peptide was represented by the area under the curve (AUC) of all its 
transitions normalized to the total AUC of all transitions from the most 
nearby (sharing a similar hydrophobicity) heavy isotope- labeled peptide 
from MyPro- SRM Internal Control Mixture spiked in before the SRM 
analysis. Absolute quantification of each protein is performed through ap-
plying AQUA Peptides (Sigma- Aldrich, St. Louis, MO).
Immunohistochemistry
Localization of MRP4 was explored in a representative subpopulation of 
sample set 1. Immunohistochemistry was performed using an immunoper-
oxidase staining method for amplified antigen detection. Sections of 4- μm 
thick cortex were gained from formalin- fixed, paraffin- embedded, post-
mortem kidney tissue blocks and were mounted on glass slides. They were 
heated at 60°C for 30 minutes, deparaffinized in xylene, and rehydrated 
with a series of graded ethanol. Enhanced antigen retrieval was performed 
by treating slides in TRIS- EDTA (10 mM Tris base; 1 mM EDTA solution; 
0.05% Tween 20; and pH 9.0) for 15 minutes at 98°C. Endogenous peroxi-
dase activity was quenched by incubating slides in 3% H2O2 for 30 minutes 
at room temperature. The sections were blocked with Avidin/Biotin block-
ing solution (Vector Laboratories, Burlingame, CA) for 15 minutes each.
Primary antibodies rat anti- MRP4 (ab15598 Abcam, Cambridge, UK) 
at dilution of 1:20 were incubated over night at 4°C in 1% bovine serum 
albumin. A biotinylated secondary rabbit anti- rat serum (R1371B, Acris 
Antibodies GmbH, Herford, DE) at dilution of 1:1,000 was then applied 
for 30 minutes. Immunoreactive sides were detected using the ABC kit 
(Vector Laboratories) for 30 minutes and 3,3 diaminobenzidine tetrahy-
drochloride (Sigma- Aldrich) solution staining for 15 minutes. The nuclei 
were counterstained with Mayers Hematoxylin Solution (Sigma- Aldrich). 
One negative- control staining lacking the primary antibody was performed 
for every age group.
Data analysis and statistics
Data were expressed as median (range). Kruskal– Wallis tests with 
Dunn’s post hoc test were used for multiple comparisons of expression lev-
els between age groups, using the P values adjusted for multiple testing. If 
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no difference in expression was found between age groups, the ontogeny 
would be referred to as “stable.” Sigmoidal Emax models are used often 
for maturational processes as it allows gradual maturation of clearance 
in early life and a “mature” clearance to be achieved at a later age.49 
Therefore, Emax models were used to fit the protein abundance data on a 
continuous scale of age for those transporters that showed between- group 
differences. The data point from the term newborn in this set of data was 
excluded prior to fitting to eliminate bias, as it was the only sample quan-
tified for that age group. We first set the median of adult data to be 100% 
and then normalized the data points from pediatric samples toward the 
median of adult data. Potential outliers were assessed and excluded using 
the Robust Regression followed by Outlier Identification method during 
the model fit process.50 The age at which TM50 was reached was deter-
mined from the Emax model. Visual inspection and 95% confidence inter-
val of the Emax parameter estimates were used to assess the goodness- of- fit 
of the sigmoidal model. Spearman’s correlation analysis was used to eval-
uate the relationship between mRNA and protein abundances within 
the same and among other transporters.
For the analysis of staining intensity after immunohistochemistry, a semiquan-
titative scoring system was used, graded by two observers (B.D.vG. and M.D.vB.) 
who independently confirmed cell staining intensity as negative (0), low staining 
(+1), or high staining (+2). Simultaneously, the localization of MRP4 in the kid-
ney tissue was determined for each sample by the same observers.
Statistical analysis was performed using IBM SPSS Statistics software 
version 21.0 (Armonk, NY), and a significance level of P < 0.05 was 
used throughout the study. Graphical exploration was performed using 
GraphPad Prism software version 5.00 (La Jolla, CA).
SUPPORTING INFORMATION
Supplementary information accompanies this paper on the Clinical 
Pharmacology & Therapeutics website (www.cpt-journal.com).
Figure S1. Correlations between mRNA expressions and protein expres-
sions (Spearman’s correlation coefficient, rs).
Table S1. Mann–Whitney U-test to examine the differences in mRNA and 
protein expression between girls and boys.
Table S2. Kruskal–Wallis followed by multiple comparisons to examine 
the differences in mRNA expression between African American and 
white subjects in different age groups.
Table S3. Mann–Whitney U-test to examine the differences in protein 
expression levels between African American adults and white adults.
Table S4. Relative mRNA expression of 11 transporters and PXR in dif-
ferent age groups.
Table S5. Absolute abundance of nine selected renal membrane trans- 
porters.
Table S6. Primer sequences used for sample set 1.
Table S7. Surrogate peptides for each of the renal membrane transport-
ers studied and their corresponding MS/MS parameters.
Material S1. RT- qPCR protocol sample set 1 and sample set 2.
Material S2. Detail description of LC- MS sample preparation and method 
parameters for quantitative proteomics.
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